Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 4005 participants.
Also called NCT06307652
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,005 participants
- Sponsor
- Registry
-
NCT06307652 -
2023-508162-15-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Saudi Arabia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06307652. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-12 (actual); primary completion 2027-04-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
- Acronym
- BalanceD-HF
- Condition
- Heart Failure and Impaired Kidney Function
- Intervention (Drug)
- balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug)
- balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg
- Intervention (Drug)
- dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06307652- Content hash
0fd33291a10b18523ac500935d7666a9f484226bdd86c061d341def0146b4fb1